{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:44:57Z","timestamp":1790347497626,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite advances in treatment and the expansion of standard care, pneumonia remains a major cause of mortality. It frequently leads to complications such as septic shock and acute respiratory distress syndrome (ARDS), both of which carry high fatality rates. Although antimicrobial therapy is the cornerstone of treatment, additional supportive care and adjunctive therapies, such as corticosteroids, are often required, especially in severe community-acquired pneumonia (CAP).<\/jats:p>\n          <jats:p>Recent updates to major guidelines on CAP, sepsis, ARDS, and critical illness-related corticosteroid insufficiency generally support corticosteroid use in severe CAP. However, the REMAP-CAP randomized controlled trial, published in 2025, failed to demonstrate significant benefit, potentially influencing future recommendations. Currently, corticosteroid therapy should be individualized based on CAP severity, particularly the degree of hypoxemia and respiratory failure. In eligible patients, early initiation and flexible duration of corticosteroid use based on clinical response may be appropriate. For nonbacterial pneumonia, strong evidence supporting corticosteroid use exists only for COVID-19 and <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia in HIV-infected individuals. Conversely, observational data do not support corticosteroid use for influenza or fungal infections. In CAP complicated by septic shock or ARDS, corticosteroid use is endorsed by recent guidelines; however, the recommended timing, dosage, and duration vary. Although combination therapy with hydrocortisone and fludrocortisone is a potential option, further direct evidence is needed. Biomarkers such as C-reactive protein and, in the near future, insights into corticosteroid-related immune repair mechanisms in COVID-19 may aid in identifying corticosteroid-responsive phenotypes.<\/jats:p>","DOI":"10.1186\/s40560-025-00809-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:31:00Z","timestamp":1751358660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current corticosteroid therapeutic strategy for community-acquired pneumonia in adults: indications, dosage, and timing"],"prefix":"10.1186","volume":"13","author":[{"given":"Seitaro","family":"Fujishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"809_CR1","first-page":"101161","volume":"55","author":"A Dinh","year":"2025","unstructured":"Dinh A, Barbier F, Bedos JP, Blot M, Cattoir V, Claessens YE, et al. Update of guidelines for management of community acquired pneumonia in adults by the French infectious disease society (SPILF) and the French-speaking society of respiratory diseases (SPLF): endorsed by the French intensive care society (SRLF), the French microbiology society (SFM), the French radiology society (SFR) and the French emergency society (SFMU). Respir Med Res. 2025;55:101161.","journal-title":"Respir Med Res"},{"key":"809_CR2","unstructured":"The JRS Guideline for the Management of Pneumonia in Adults 2024 Writing Committee. The JRS Guideline for the Management of Pneumonia in Adults 2024 (in Japanese); 2024."},{"key":"809_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","volume":"49","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49:615\u201332.","journal-title":"Intensive Care Med"},{"key":"809_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-025-00776-0","volume":"13","author":"N Shime","year":"2025","unstructured":"Shime N, Nakada TA, Yatabe T, Yamakawa K, Aoki Y, Inoue S, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2024. J Intensive Care. 2025;13: 15.","journal-title":"J Intensive Care"},{"key":"809_CR5","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:e1063\u2013143.","journal-title":"Crit Care Med"},{"key":"809_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1164\/rccm.202311-2011ST","volume":"209","author":"N Qadir","year":"2024","unstructured":"Qadir N, Sahetya S, Munshi L, Summers C, Abrams D, Beitler J, et al. An update on management of adult patients with acute respiratory distress syndrome: an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2024;209:24\u201336.","journal-title":"Am J Respir Crit Care Med"},{"key":"809_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","volume":"49","author":"G Grasselli","year":"2023","unstructured":"Grasselli G, Calfee CS, Camporota L, Poole D, Amato MBP, Antonelli M, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49:727\u201359.","journal-title":"Intensive Care Med"},{"key":"809_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40560-022-00615-6","volume":"10","author":"S Tasaka","year":"2022","unstructured":"Tasaka S, Ohshimo S, Takeuchi M, Yasuda H, Ichikado K, Tsushima K, et al. ARDS clinical practice guideline 2021. J Intensive Care. 2022;10:32.","journal-title":"J Intensive Care"},{"key":"809_CR9","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/CCM.0000000000006172","volume":"52","author":"D Chaudhuri","year":"2024","unstructured":"Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med. 2024;52:e219\u201333.","journal-title":"Crit Care Med"},{"key":"809_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bja.2023.10.034","volume":"132","author":"GD Nethathe","year":"2024","unstructured":"Nethathe GD, Lipman J, Anderson R, Fuller PJ, Feldman C. Glucocorticoids with or without fludrocortisone in septic shock: a narrative review from a biochemical and molecular perspective. Br J Anaesth. 2024;132:53\u201365.","journal-title":"Br J Anaesth"},{"key":"809_CR11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3389\/fimmu.2018.01736","volume":"9","author":"N Heming","year":"2018","unstructured":"Heming N, Sivanandamoorthy S, Meng P, Bounab R, Annane D. Immune effects of corticosteroids in sepsis. Front Immunol. 2018;9:1736.","journal-title":"Front Immunol"},{"key":"809_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","volume":"40","author":"RA Panettieri","year":"2019","unstructured":"Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40:38\u201349.","journal-title":"Trends Pharmacol Sci"},{"key":"809_CR13","doi-asserted-by":"publisher","first-page":"T107","DOI":"10.1530\/JOE-16-0659","volume":"234","author":"S Ruhs","year":"2017","unstructured":"Ruhs S, Nolze A, Hubschmann R, Grossmann C. 30 years of the mineralocorticoid receptor: nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234:T107\u201324.","journal-title":"J Endocrinol"},{"key":"809_CR14","doi-asserted-by":"publisher","first-page":"E994","DOI":"10.1152\/ajpendo.00345.2014","volume":"307","author":"I Cortes-Puch","year":"2014","unstructured":"Cortes-Puch I, Hicks CW, Sun J, Solomon SB, Eichacker PQ, Sweeney DA, et al. Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia. Am J Physiol Endocrinol Metab. 2014;307:E994-1008.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"809_CR15","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00134-012-2735-5","volume":"38","author":"CW Hicks","year":"2012","unstructured":"Hicks CW, Sweeney DA, Danner RL, Eichacker PQ, Suffredini AF, Feng J, et al. Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia. Intensive Care Med. 2012;38:2063\u201371.","journal-title":"Intensive Care Med"},{"key":"809_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/CCM.0b013e31822efa14","volume":"40","author":"CW Hicks","year":"2012","unstructured":"Hicks CW, Sweeney DA, Danner RL, Eichacker PQ, Suffredini AF, Feng J, et al. Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock. Crit Care Med. 2012;40:199\u2013207.","journal-title":"Crit Care Med"},{"key":"809_CR17","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"PF Dequin","year":"2023","unstructured":"Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388:1931\u201341.","journal-title":"N Engl J Med"},{"key":"809_CR18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","volume":"48","author":"GU Meduri","year":"2022","unstructured":"Meduri GU, Shih MC, Bridges L, Martin TJ, El-Solh A, Seam N, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022;48:1009\u201323.","journal-title":"Intensive Care Med"},{"key":"809_CR19","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1093\/cid\/ciad496","volume":"77","author":"F Bergmann","year":"2023","unstructured":"Bergmann F, Pracher L, Sawodny R, Blaschke A, Gelbenegger G, Radtke C, et al. Efficacy and safety of corticosteroid therapy for community-acquired pneumonia: a meta-analysis and meta-regression of randomized, controlled trials. Clin Infect Dis. 2023;77:1704\u201313.","journal-title":"Clin Infect Dis"},{"key":"809_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00134-025-07861-w","volume":"51","author":"The REMAP-CAP Investigators","year":"2025","unstructured":"The REMAP-CAP Investigators, Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: the REMAP-CAP corticosteroid domain randomized clinical trial. Intensive Care Med. 2025;51:665\u201380.","journal-title":"Intensive Care Med"},{"key":"809_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1056\/NEJMra1714562","volume":"380","author":"LA Mandell","year":"2019","unstructured":"Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380:651\u201363.","journal-title":"N Engl J Med"},{"key":"809_CR22","doi-asserted-by":"publisher","first-page":"103080","DOI":"10.1016\/j.eclinm.2025.103080","volume":"81","author":"Group RC","year":"2025","unstructured":"Group RC. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine. 2025;81:103080.","journal-title":"EClinicalMedicine"},{"key":"809_CR23","doi-asserted-by":"crossref","unstructured":"recoverytrial@ndph.ox.ac.uk RCGEa, Group RC. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023;401:1499\u2013507.","DOI":"10.1016\/S0140-6736(23)00510-X"},{"key":"809_CR24","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Bethesda (MD): National Institutes of Health; 2021."},{"key":"809_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00134-022-06726-w","volume":"48","author":"A Torres","year":"2022","unstructured":"Torres A, Motos A, Cilloniz C, Ceccato A, Fern\u00e1ndez-Barat L, Gabarrus A, et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022;48:850\u201364.","journal-title":"Intensive Care Med"},{"key":"809_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13613-020-0642-4","volume":"10","author":"MJ Tsai","year":"2020","unstructured":"Tsai MJ, Yang KY, Chan MC, Kao KC, Wang HC, Perng WC, et al. Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study. Ann Intensive Care. 2020;10:26.","journal-title":"Ann Intensive Care"},{"key":"809_CR27","doi-asserted-by":"publisher","first-page":"E98","DOI":"10.1097\/CCM.0000000000004093","volume":"48","author":"LE Lansbury","year":"2020","unstructured":"Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020;48:E98\u2013106.","journal-title":"Crit Care Med"},{"key":"809_CR28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00134-018-5332-4","volume":"44","author":"G Moreno","year":"2018","unstructured":"Moreno G, Rodriguez A, Reyes LF, Gomez J, Sole-Violan J, Diaz E, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018;44:1470\u201382.","journal-title":"Intensive Care Med"},{"key":"809_CR29","unstructured":"U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Association, Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Bethesda (MD): National Institutes of Health; 2024."},{"key":"809_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13613-020-00649-9","volume":"10","author":"L Ding","year":"2020","unstructured":"Ding L, Huang HX, Wang HY, He HY. Adjunctive corticosteroids may be associated with better outcome for non-HIV pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care. 2020;10:34.","journal-title":"Ann Intensive Care"},{"key":"809_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12281-023-00456-2","volume":"17","author":"Z Li","year":"2023","unstructured":"Li Z, Denning DW. The impact of corticosteroids on the outcome of fungal disease: a systematic review and meta-analysis. Curr Fungal Infect Rep. 2023;17:54\u201370.","journal-title":"Curr Fungal Infect Rep"},{"key":"809_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","volume":"183","author":"AH Limper","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96\u2013128.","journal-title":"Am J Respir Crit Care Med"},{"key":"809_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1378\/chest.129.4.968","volume":"129","author":"T Dremsizov","year":"2006","unstructured":"Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest. 2006;129:968\u201378.","journal-title":"Chest"},{"key":"809_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145929","volume":"11","author":"B Montull","year":"2016","unstructured":"Montull B, Menendez R, Torres A, Reyes S, Mendez R, Zalacain R, et al. Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. PLoS ONE. 2016;11: e0145929.","journal-title":"PLoS ONE"},{"key":"809_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1705835","volume":"378","author":"B Venkatesh","year":"2018","unstructured":"Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378:797\u2013808.","journal-title":"N Engl J Med"},{"key":"809_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1705716","volume":"378","author":"D Annane","year":"2018","unstructured":"Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378:809\u201318.","journal-title":"N Engl J Med"},{"key":"809_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/08850666241248568","volume":"39","author":"G Kasotakis","year":"2024","unstructured":"Kasotakis G, Pant P, Patel AD, Ahmed Y, Raghunathan K, Krishnamoorthy V, et al. Hospital outcomes in patients who developed acute respiratory distress syndrome after community-acquired pneumonia. J Intensive Care Med. 2024;39:994\u20131001.","journal-title":"J Intensive Care Med"},{"key":"809_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","volume":"8","author":"J Villar","year":"2020","unstructured":"Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267\u201376.","journal-title":"Lancet Respir Med"},{"key":"809_CR39","doi-asserted-by":"publisher","first-page":"e000420","DOI":"10.1136\/bmjresp-2019-000420","volume":"6","author":"MJD Griffiths","year":"2019","unstructured":"Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6:e000420.","journal-title":"BMJ Open Respir Res"},{"key":"809_CR40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/aas.12713","volume":"60","author":"J Claesson","year":"2016","unstructured":"Claesson J, Freundlich M, Gunnarsson I, Laake JH, Moller MH, Vandvik PO, et al. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand. 2016;60:697\u2013709.","journal-title":"Acta Anaesthesiol Scand"},{"key":"809_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4046\/trd.2016.79.4.214","volume":"79","author":"YJ Cho","year":"2016","unstructured":"Cho YJ, Moon JY, Shin ES, Kim JH, Jung H, Park SY, et al. Clinical practice guideline of acute respiratory distress syndrome. Tuberculosis Respir Dis. 2016;79:214\u201333.","journal-title":"Tuberculosis Respir Dis"},{"key":"809_CR42","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jama.288.7.862","volume":"288","author":"D Annane","year":"2002","unstructured":"Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862\u201371.","journal-title":"JAMA"},{"key":"809_CR43","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1002\/ams2.563","volume":"7","author":"R Yamamoto","year":"2020","unstructured":"Yamamoto R, Nahara I, Toyosaki M, Fukuda T, Masuda Y, Fujishima S. Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta-analysis. Acute Med Surg. 2020;7:e563.","journal-title":"Acute Med Surg"},{"key":"809_CR44","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300034","author":"R Pirracchio","year":"2023","unstructured":"Pirracchio R, Annane D, Waschka AK, Lamontagne F, Arabi YM, Bollaert PE, et al. Patient-level meta-analysis of low-dose hydrocortisone in adults with septic shock. NEJM Evid. 2023. https:\/\/doi.org\/10.1056\/EVIDoa2300034.","journal-title":"NEJM Evid"},{"key":"809_CR45","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.202310-1785OC","volume":"209","author":"B Teja","year":"2024","unstructured":"Teja B, Berube M, Pereira TV, Law AC, Schanock C, Pang B, et al. Effectiveness of fludrocortisone plus hydrocortisone versus hydrocortisone alone in septic shock: a systematic review and network meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 2024;209:1219\u201328.","journal-title":"Am J Respir Crit Care Med"},{"key":"809_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jamainternmed.2023.0258","volume":"183","author":"NA Bosch","year":"2023","unstructured":"Bosch NA, Teja B, Law AC, Pang B, Jafarzadeh SR, Walkey AJ. Comparative effectiveness of fludrocortisone and hydrocortisone vs hydrocortisone alone among patients with septic shock. JAMA Intern Med. 2023;183:451\u20139.","journal-title":"JAMA Intern Med"},{"key":"809_CR47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S2213-2600(23)00430-7","volume":"12","author":"N Heming","year":"2024","unstructured":"Heming N, Renault A, Kuperminc E, Brun-Buisson C, Megarbane B, Quenot JP, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med. 2024;12:366\u201374.","journal-title":"Lancet Respir Med"},{"key":"809_CR48","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-024-07552-y","volume":"50","author":"B Teja","year":"2024","unstructured":"Teja B, Pereira TV, Law AC, Mazer CD, Bosch NA. Effectiveness of fludrocortisone and hydrocortisone versus hydrocortisone alone in septic shock with and without pneumonia. Intensive Care Med. 2024;50:1535\u20137.","journal-title":"Intensive Care Med"},{"key":"809_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jama.2010.2","volume":"303","author":"CS Investigators","year":"2010","unstructured":"Investigators CS, Annane D, Cariou A, Maxime V, Azoulay E, D\u2019Honneur G, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010;303:341\u20138.","journal-title":"JAMA"},{"key":"809_CR50","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1007\/s00134-024-07616-z","volume":"50","author":"J Walsham","year":"2024","unstructured":"Walsham J, Hammond N, Blumenthal A, Cohen J, Myburgh J, Finfer S, et al. Fludrocortisone dose\u2013response relationship in septic shock: a randomised phase II trial. Intensive Care Med. 2024;50:2050\u201360.","journal-title":"Intensive Care Med"},{"key":"809_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/jir.2022.0029","volume":"42","author":"LM Pacheco-Hernandez","year":"2022","unstructured":"Pacheco-Hernandez LM, Ramirez-Noyola JA, Gomez-Garcia IA, Ignacio-Cortes S, Zuniga J, Choreno-Parra JA. Comparing the cytokine storms of COVID-19 and pandemic influenza. J Interferon Cytokine Res. 2022;42:369\u201392.","journal-title":"J Interferon Cytokine Res"},{"key":"809_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41591-021-01576-3","volume":"28","author":"S Sinha","year":"2022","unstructured":"Sinha S, Rosin NL, Arora R, Labit E, Jaffer A, Cao L, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat Med. 2022;28:201\u201311.","journal-title":"Nat Med"},{"key":"809_CR53","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/s41467-024-49756-2","volume":"15","author":"LPA Neyton","year":"2024","unstructured":"Neyton LPA, Patel RK, Sarma A, Consortium UC, Willmore A, Haller SC, et al. Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19. Nat Commun. 2024;15:5483.","journal-title":"Nat Commun"},{"issue":"4318\u201335","key":"809_CR54","first-page":"e20","volume":"187","author":"R Knoll","year":"2024","unstructured":"Knoll R, Helbig ET, Dahm K, Bolaji O, Hamm F, Dietrich O, et al. The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation. Cell. 2024;187(4318\u201335):e20.","journal-title":"Cell"},{"key":"809_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-2600(24)00405-3","volume":"13","author":"JM Smit","year":"2025","unstructured":"Smit JM, Van Der Zee PA, Stoof SCM, Van Genderen ME, Snijders D, Boersma WG, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med. 2025;13:221\u201333.","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-025-00809-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:07:14Z","timestamp":1751360834000},"score":1,"resource":{"primary":{"URL":"https:\/\/jintensivecare.biomedcentral.com\/articles\/10.1186\/s40560-025-00809-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1186\/s40560-025-00809-8","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}